Article
Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy.
Clinical and experimental immunology - 1 Sept 2013
Herasimtschuk A A, Hansen B R, Langkilde A, Moyle G J, Andersen O, Imami N
Abstract excerpt
Recombinant human growth hormone (rhGH) administered to combination anti-retroviral therapy (cART)-treated human immunodeficiency virus-1 (HIV-1)-infected individuals has been found to reverse thymic involution, increase total and naive CD4 T cell counts and reduce the expression of activation and apoptosis markers. To date, such studies have used high, pharmacological doses of rhGH. In this substudy, samples...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.